Meet DIMA BIOTECH at the 5th GPCR-Targeted Drug Discovery Summit

Dear GPCR Researchers,

GPCR targets continue to present challenges in maintaining native structure and functional relevance in discovery and assay development workflows. We provide validated tools designed to support your GPCR research:

200+ in-stock GPCR nanodisc full-length proteins with preserved native structure and functional activity
80+ flow cytometry, validated GPCR monoclonal antibodies for reliable live cell based functional assays
Custom GPCR solutions, including nanodisc proteins and antibody development for complex targets

Video: Develop GPCR Antibodies with Full-Length Nanodisc Proteins

Our team will be in Boston next week for the GPCR-Targeted Drug Discovery Summit. If you are attending, we welcome a brief meeting to discuss your GPCR projects.

Schedule a meeting to discuss your GPCR project

Resources

Syndisc ^TM(Polymer-Based)

PeptiNanodisc^TM(Peptide-Based)

Use DIMA's Nanodisc and PeptiNanodisc in immunology to screen mAbs

A case of Nanodisc Used in mAbs Development as Immunogen

DIMA BIOTECH Highlights

Digital Resources

Nanodisc Flyer

DiNabody

Anti-GPRC5D CAR T-cell therapy

CLDN18.2 ECL1 Loop-specific mAb

GPCR Target Landscape: From CXCR4 to GPRC5D Which GPCR Targets Are Gaining Momentum in oncology at 2026 AACR

[AACR 2026] From CXCR4 to GPRC5D: Which GPCR Targets Are Gaining Momentum in Oncology

AACR 2026 trends clearly indicate a turning point. GPCR-related research is rapidly expanding beyond traditional small-molecule receptor modulation into tumor...

31
Mar

Membrane Protein Antibody Development: Why Nanodiscs Are Reshaping GPCR and Ion Channel Targeting

Membrane proteins are critical drug targets, but their hydrophobic and structurally complex nature has limited antibody discovery. Nanodisc technology stabilizes...

23
Jan

Optimizing GPCR Expression and Purification: Enhancing Synthetic Nanodisc Technology with Multiple Tag Strategies

1. About Synthetic Nanodisc The lipid composition of traditional membrane scaffold protein (MSP) nanodiscs often differs from that of natural...

26
Dec

DIMA BIOTECH's CXCR4 nanodisc empowers new preprint by Nobel team

DIMA BIOTECH Membrane Proteins Empower Nobel Team’s Breakthrough in GPCR Drug Discovery

DIMA’s CXCR4-Nanodisc Empowers New Preprint from David Baker, which is entitled "De novo design of miniprotein agonists and antagonists targeting G protein-coupled...

26
May

About DIMA BIOTECH

DIMA Biotechnology provides preclinical R&D solutions for BioPharma, offering 5000+ validated mAbs and 500+ full-length multipass transmembrane proteins. Our platforms include Nanodisc, single B-cell mAb discovery, and mammalian cell display for antibody engineering-advancing drug development across GPCRs, ion channels, and other high-value difficult drug targets.

Among of these platforms, DIMA BIOTECH’s unique Nanodisc platforms, including Syndisc^TM and PeptiNanodisc^TM enable the stabilization of full-length, multi-pass membrane proteins in a native-like, detergent-free environment. Expressed in HEK293 cells to preserve proper structure and post-translational modifications, these systems support high-quality, biologically active proteins.

Schedule a Meeting

Secure a one-on-one meeting with our scientists and technical experts at the 5th GPCR-Targeted Drug Discovery Summit.

Please share your details below:

About the GPCR-Targeted Drug Discovery Summit

The 5th GPCR-Targeted Drug Discovery Summit is a leading, industry-focused meeting dedicated exclusively to advancing GPCR therapeutics. As breakthroughs in cryo-EM, AI-driven structure prediction, and high-resolution screening unlock previously “undruggable” receptor families, the summit arrives at a pivotal moment for the field. With growing momentum across oncology, immunology, neurology, and rare diseases, GPCR drug discovery is entering a new era of innovation.

Bringing together top experts from biopharma and biotech, including AbbVie, Eli Lilly, and emerging innovators, the event features 25+ world-class speakers, over 20 data-driven presentations, and extensive networking opportunities. Attendees will gain insights into novel GPCR targets, cutting-edge technologies, and next-generation therapeutic strategies.